Despite promising clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering considerable opposition from managed care entities. These organizations are frequently creating limitations to reimbursement, like high expense restrictions and approval processes that restrict consumer